Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol

  • Abu Hashim Irhan Ibrahim
    Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University
  • El-dahan Marwa Salah
    Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University
  • Yusif Rehab Mohammed
    Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University
  • Abd-ElGawad Abd-ElGawad Helmy
    Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University
  • Arima Hidetoshi
    Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program,” Kumamoto University

この論文をさがす

抄録

Niosomes have been reported as possible approach to improve the low corneal penetration and bioavailability characteristics for many drugs. The purpose of this study was to prepare and characterize an effective ocular niosomal hydrogel containing 0.5% (w/v) atenolol which is β1 adrenoceptor blocker for treatment of glaucoma. Thin film hydration method was used for the preparation of niosomes using Span 60 and cholesterol at different molar ratios. Niosomes were characterized using laser diffraction particle size analyzer, transmission electron microscopy, and differential scanning calorimetry. The results showed that higher entrapment efficiency (80.7%±1.2) was obtained from niosomes prepared using Span 60/cholesterol at a 2 : 1 molar ratio. Stability study revealed that a fairly high retention of atenolol inside vesicles (83.1%±2.35) up to a period of 3 months at 4°C. It was found that niosomal hydrogel formulation using carbopol 934P significantly exhibited sustained in vitro release of the drug compared with free drug solution and other polymeric hydrogels. The intraocular pressure (IOP) lowering activity of selected atenolol formulations was determined and compared with that of atenolol solution. It is worth noting that niosomal hydrogel formulation was found to show the most significant prolonged decrease in IOP, suggesting that niosomal hydrogel could be a promising delivery system for atenolol.

収録刊行物

参考文献 (18)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ